Ensuring that the right patients get the right treatments at the right time

Real World Strategy & Analytics

The RWS&A group is home to industry-leading experts in establishing evidence development and dissemination strategy. We partner with customers around the world to create tailor-made solutions to support an integrated outcomes strategy encompassing safety, effectiveness, and economic endpoints. We provide guidance that’s unmatched in the industry by combining our expertise in strategic consulting, market access, evidence synthesis, health economics, outcomes, and epidemiology services. We work with you to identify and communicate key values of every treatment, and help ensure that the right medicine is available to the right patients.

Strategic Consulting, HTA, and Market Access
Mapi has strong experience in providing global strategic Health Technology Assessment (HTA) expertise in combination with the right analytics and evidence to reach a target price and optimize patient access to new treatments. With our deep understanding of every integral part of the evidence development process, plus our industry-leading experience in the market access challenges that the industry faces, we help our clients develop a robust strategy that identifies the evidence required for all key stakeholders to support marketing authorization and HTA reimbursement decision-making.

Our in-house team of experienced HTA and access experts, medical writers, health economists, and systematic reviewers enable us to provide our clients with the complete package of HTA, strategy, and communication services to achieve global market access including value identification, stakeholder intelligence, strategic consulting, value communications, and HTA, pricing, and reimbursement services.

Our multidisciplinary team gathers insights from stakeholders and transforms them into strategies that
can guide access decision-making throughout the product life cycle. We develop evidence dissemination messaging that ensures early evidence generation informed by integrated scientific advice supports the value story and market access strategy. These communications include Global Value Dossiers, scientific advice briefing books, publications, training slide sets, payer and clinician advisory boards and workshops, local market access support, and finally the HTA dossiers and support for local market uptake.

We specialize in developing and supporting strategies that address the unique challenges facing market access for specialty products and rare diseases, where communicating benefit-risk and the patient voice is crucial to successful market access.

Data Analytics & Epidemiology
Mapi’s talent pool of scientists includes a number of epidemiologists and outcomes research scientists who are deeply familiar with secondary data sources around the globe. Clients who wish to understand the real-world use of their products in the most naturalistic, cost-effective, and time-efficient way are keenly interested in tapping these rich data sources to profile burden of illness, patterns of use, and even prescriber or patient experiences when the latter can be surveyed.

Mapi’s expert team advises clients on the optimal data sources to employ, depending on the outcomes and
the markets of interest. Our strategy often begins with a comprehensive database/data source ‘mapping’ to identify secondary data resources, ending with an elegant evaluation of the identified data sources. Our experts also understand limitations of secondary data resources for some research objectives, and can advise alternative strategies such as hybrid study designs to ensure research goals are met.

Additionally, Mapi’s epidemiologists have a laser focus on patient safety and a great deal of experience with US REMS and EU-RMP design, implementation, and effectiveness assessments. All of Mapi’s epidemiologists, outcomes research scientists, and analysts are trained in the art and the science of robust literature reviews; whether clients need a simple (and rapid) safety review, structured or systematic literature review, or full meta-analysis, Mapi’s team delivers robust results.

Modeling and Evidence Synthesis
Mapi’s modeling experts have extensive experience in developing models to support your economic value proposition. We work with our clients to understand their needs before delivering bespoke economic models, including cost-effectiveness and budget impact models, that deliver the metrics needed to demonstrate the health economic value of their product. Our systematic literature reviews collect and critically analyze multiple research studies, and our expert team uses advanced statistical methods in conducting meta-analyses to synthesize data across multiple studies.

Request a consultation with an RWS&A expert

First Name* Last Name*
Job Title Company Country* Your Email*
Phone number* Mobile number
What would you like to enquire about? Subscribe to receive ICON updates?

Please read Mapi Privacy Policy, any personal data you submit to us as part of your enquiry will be processed by Mapi in accordance with the Mapi privacy policy.